Bellevue Group’s Health Catalyst HCAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-424,611
Closed -$6.15M 179
2022
Q2
$6.15M Hold
424,611
0.09% 109
2022
Q1
$11.1M Sell
424,611
-268,055
-39% -$7.61M 0.13% 104
2021
Q4
$27.4M Sell
692,666
-34,567
-5% -$1.58M 0.28% 91
2021
Q3
$36.4M Sell
727,233
-26,388
-4% -$1.44M 0.37% 84
2021
Q2
$41.8M Buy
753,621
+11,766
+2% +$627K 0.41% 77
2021
Q1
$34.7M Buy
741,855
+121,645
+20% +$5.89M 0.37% 84
2020
Q4
$27M Buy
620,210
+98,314
+19% +$3.63M 0.31% 85
2020
Q3
$19.1M Buy
521,896
+172,727
+49% +$5.87M 0.26% 91
2020
Q2
$10.2M Buy
349,169
+96,169
+38% +$2.66M 0.14% 108
2020
Q1
$6.62M Buy
253,000
+28,492
+13% +$871K 0.13% 105
2019
Q4
$7.79M Buy
224,508
+64,292
+40% +$2.13M 0.12% 102
2019
Q3
$5.07M Buy
+160,216
New +$6.31M 0.09% 109

Other funds holding HCAT